| The most common TEAEs overall in the 6 patients treated with SGN‐2FF in part B were diarrhea (67%), fatigue (50%), and nausea (50%) and in the seven patients treated with SGN‐2FF + pembrolizumab were decreased appetite (57%), fatigue (57%), and back pain (57%). During part B, there were no SAEs reported. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.